It is an aminoglycoside antibiotic produced by the strain of Streptosporangium sibiricum. It has anti-bacterial effect and has an inhibitory effect on reticuloendothelial sarcoma RAB-1 and oncogenic AK/LY cells. Two times of the maximum tolerated dose of intravenous administration can inhibit OZH-5 tumor and lymphosarcoma Lic-1. It has very high DNA binding affinity and cytotoxicity against cancer cell lines.
Structure of 12684-33-2
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Sibiromycin is a potent antitumor antibiotic and a promising ADC cytotoxin utilized as an ADC payload in antibody-drug conjugates. Its mechanism involves binding to DNA and inducing strand breaks, leading to apoptosis in rapidly proliferating tumor cells. The high cytotoxicity of Sibiromycin makes it an attractive payload for targeted cancer therapies, especially when incorporated into ADC platforms designed for selective tumor delivery.
Within antibody-drug conjugates, Sibiromycin is conjugated to monoclonal antibodies via cleavable or non-cleavable linker chemistries. This design ensures that the payload remains inactive during systemic circulation and is selectively released inside tumor cells after internalization and enzymatic processing. Such tumor-specific delivery enhances antitumor efficacy while minimizing off-target toxicity, making Sibiromycin a reliable option for precision oncology applications where potent cytotoxic activity is required at low drug-to-antibody ratios (DARs).
Applications of Sibiromycin include its use in preclinical and clinical ADC candidates targeting hematologic malignancies and solid tumors, such as leukemia, lymphoma, breast cancer, and lung cancer. Its chemical structure supports compatibility with diverse linker technologies, optimizing payload stability, conjugation efficiency, and intracellular release. Researchers utilize Sibiromycin to develop next-generation ADCs with enhanced tumor selectivity, improved pharmacokinetics, and potent antitumor activity, enabling innovative and effective targeted cancer therapies.
What is Sibiromycin?
Sibiromycin is a naturally derived cytotoxic antibiotic that binds DNA, inhibiting replication and transcription. It is used as a payload in ADCs for targeted cell killing, and its chemical structure allows efficient antibody conjugation.
22/9/2017
Could you kindly advise how Sibiromycin is used in ADCs?
In ADCs, Sibiromycin is attached to antibodies to deliver cytotoxicity selectively to cells expressing specific antigens, reducing off-target toxicity and improving therapeutic index for experimental and preclinical studies.
17/8/2018
Dear team, which linkers are compatible with Sibiromycin ADCs?
Sibiromycin can be conjugated using cleavable linkers for intracellular payload release or non-cleavable linkers for increased systemic stability. Linker selection influences ADC pharmacokinetics and efficacy.
26/2/2020
Could you please advise what handling precautions are necessary for Sibiromycin?
Due to its potent cytotoxicity, Sibiromycin must be handled in controlled laboratory conditions with PPE and containment. Strict adherence to safety protocols is essential during conjugation and experimental handling.
22/12/2018
Good morning! What benefits do Sibiromycin ADCs provide in research?
Sibiromycin ADCs enable targeted cytotoxicity for preclinical evaluation of antibody specificity and payload efficiency. They support research in oncology therapeutics and allow controlled study of ADC pharmacodynamics and pharmacokinetics.
21/2/2018
— Dr. Kevin Wallace, Senior Scientist (USA)
Sibiromycin from BOC Sciences arrived with excellent purity, enabling accurate ADC conjugation.
26/2/2020
— Dr. Matteo Rossi, Molecular Pharmacologist (Italy)
Sibiromycin from BOC Sciences was highly effective for our early-stage drug discovery project. The material quality and reproducibility supported smooth downstream workflows.
21/2/2018
— Dr. Hans Bauer, Medicinal Chemist (Germany)
Fast shipping, thorough QC, and responsive technical support for Sibiromycin.
22/12/2018
— Ms. Caroline Dubois, Molecular Oncology Scientist (France)
Sibiromycin from BOC Sciences met the stringent criteria of our preclinical program. The batch-to-batch uniformity and thorough QC gave us a dependable foundation for downstream research.
22/9/2017
— Dr. Richard Moore, Lead Scientist (USA)
High-purity Sibiromycin and timely delivery enabled efficient pipeline progression.
— Dr. Richard Evans, Drug Discovery Scientist (UK)
Our group evaluated Sibiromycin for novel payload development, and the sample from BOC Sciences was both potent and reproducible. Delivery was punctual, which helped us meet a grant milestone.
17/8/2018
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.